Jean‐Pierre Gotteland

Inhibition of c‐Jun N‐terminal kinase decreases cardiomyocyte apoptosis and infarct size after myocardial ischemia and reperfusion in anaesthetized rats

Chiara Ferrandi, Rossana Ballerio, P. Gaillard et al. · British Journal of Pharmacology · 2004 · 147 citations · Full text

Medicine, Cardiology, Pharmacology +17

Design and Synthesis of the First Generation of Novel Potent, Selective, and in Vivo Active (Benzothiazol-2-yl)acetonitrile Inhibitors of the c-Jun N-Terminal Kinase

P. Gaillard, Isabelle Jeanclaude-Etter, Vittoria Ardissone et al. · Journal of Medicinal Chemistry · 2005 · 126 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial

Jacques Donnez, Hugh S. Taylor, Robert N. Taylor et al. · Fertility and Sterility · 2020 · 115 citations · Full text

Medicine, Gynecology, Pharmacotherapy +11

AS601245 (1,3-Benzothiazol-2-yl (2-{[2-(3-pyridinyl) ethyl] amino}-4 pyrimidinyl) Acetonitrile): A c-Jun NH2-Terminal Protein Kinase Inhibitor with Neuroprotective Properties

Sonia Carboni, Agnes Hiver, Cédric Szyndralewiez et al. · Journal of Pharmacology and Experimental Therapeutics · 2004 · 106 citations

Life Sciences, Neurobiology, Neuroscience +17

Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials

Jacques Donnez, Hugh S. Taylor, Elizabeth A. Stewart et al. · The Lancet · 2022 · 72 citations

Medicine, Gynecology, Pharmacotherapy +9